Combo therapy does not affect COPD death rate, but improves breathing, report finds

Share this article:

The use of a steroid-plus-bronchodilator won't lower the death risk for patients with chronic obstructive pulmonary disease, but it will likely improve quality of life, according to new research results.

There was no notable difference in the mortality of COPD suffers who used Advair, an inhaled steroid combined with a long-acting bronchodilator, versus those given a placebo, according to researchers at the University of Liverpool and University Hospital Aintree. But researchers who studied more than 6,100 people with the condition noticed a 25% decline in breathing and health problems associated with the progressive, debilitating lung disease.

Study participants were randomly assigned the use of the long-acting bronchodilator salmeterol alone, the inhaled steroid fluticasone propionate alone, salmeterol plus fluticasone in combination (sold as Advair), or a placebo.

The full study appears in the New England Journal of Medicine.
Share this article:

More in News

Hospitals in the Midwest refer patients to the broadest networks of skilled nursing facilities, study finds

Hospitals in the Midwest refer patients to the ...

Midwestern hospitals spread referrals to the greatest variety of skilled nursing facilities and tap their favorite SNFs least often, according to a recently published analysis of nationwide referral patterns.

Bill would affect pay, scheduling for some nursing home housekeeping staff

Nursing homes could face more stringent scheduling requirements for housekeeping workers and might be on the hook to compensate them for last-minute shift changes under a bill proposed in both houses of Congress.

Joint Commission adds memory care accreditation

New memory care accreditation for nursing homes encourages staff to use a flexible, problem-solving approach to care for those with dementia, according to Joint Commission guidelines.